The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Open accessAbstract
Aims: Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus ( T2DM ). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [ CKD ; estimated glomerular filtration rate ( eGFR ) ≥30 and <50 ml /min/1.73 m 2 ]. Methods: In this randomized, double‐blind, placebo‐controlled, phase 3 trial, subjects (N = 269) received canagliflozin 100 or 300 mg or placebo daily. The primary efficacy endpoint was change from baseline in HbA1c at week 26. Prespecified secondary endpoints were change in fasting plasma glucose ( FPG ) and proportion of subjects reaching HbA1c <7.0%. Safety was assessed based on adverse event ( AE ) reports; renal safety parameters (e.g. eGFR , blood urea nitrogen and albumin/creatinine ratio) were also evaluated. Results: Both canagliflozin 100 and 300 mg reduced HbA1c from baseline compared with placebo at week 26 (–0.33, –0.44 and –0.03%; p < 0.05). Numerical reductions in FPG and higher proportions of subjects reaching HbA1c < 7.0% were observed with canagliflozin 100 and 300 mg versus placebo (27.3, 32.6 and 17.2%). Overall AE rates were similar for canagliflozin 100 and 300 mg and placebo (78.9, 74.2 and 74.4%). Slightly higher rates of urinary tract infections and AEs related to osmotic diuresis and reduced intravascular volume were observed with canagliflozin 300 mg compared with other groups. Transient changes in renal function parameters that trended towards baseline over 26 weeks were observed with canagliflozin. Conclusion: Canagliflozin improved glycaemic control and was generally well tolerated in subjects with T2DM and Stage 3 CKD .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Levey, A. S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A., Kusek, J. W., Van Lente, F., & for Chronic Kidney Disease Epidemiology Collaboration (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.077180 · Cited by 1,855
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“of a medication that is associated with hypoglycaemia, like insulin or a sulphonylurea agent, an increase in hypoglycaemia is usually observed [19–23].”
Backgroundde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Hogg, R. J., Furth, S., Lemley, K. V., Portman, R., Schwartz, G. J., Coresh, J., Balk, E., Lau, J., Levin, A., Kausz, A. T., et al. (2003) · Pediatrics · doi:10.1542/peds.111.6.1416 · Cited by 700
Wolff, L. F., Smith, Q. T., Snyder, W. K., Bedrick, J. A., Liljemark, W. F., Aeppli, D. A., & Bandt, C. L. (1988) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.1988.tb01003.x · Cited by 577
Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., Capuano, G., Canovatchel, W., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421
Self-citationStrojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100332n · Cited by 385
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Screening for Kidney Disease in Adults With Diabetes
Kramer, H., & Molitch, M. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1813 · Cited by 122
Diabetes Management Issues for Patients With Chronic Kidney Disease
Cavanaugh, K. L. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.3.90 · Cited by 84
Noninsulin glucose-lowering agents for the treatment of patients on dialysis
Flynn, C. A., & Bakris, G. L. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.12 · Cited by 34
Self-citationLeiter, L. A., Cefalu, W. T., NISKANEN, L. K., et al. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.07.055 · Cited by 13
Research works printed but not linked: 6
- Polidori D, 2011, Exposure‐response modeling of canagliflozin effects on the renal glucose threshold in subjects with type 2 diabetes (T2DM) (Abstract 1072‐P), Diabetes, 60, A294
- Schernthaner G, 2012, Efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulphonylurea (Abstract 243), Diabetologia, 55, S108
- Stenlof K, 2012, Canagliflozin, a sodium glucose co‐transporter 2 inhibitor, improves glycaemic control in subjects with type 2 diabetes inadequately controlled with diet and exercise (Abstract 760), Diabetologia, 55, S312
- Wilding J, 2012, Canagliflozin, a sodium glucose co‐transporter 2 inhibitor, improves glycaemia in subjects with type 2 diabetes inadequately controlled with metformin plus sulphonylurea (Abstract 766), Diabetologia, 55, S315
- Devineni D, 2012, Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non‐diabetic subjects (Abstract PUB295), J Am Soc Nephrol, 23, 961A
- Kohan DE, 2011, Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (Abstract TH‐PO524), J Am Soc Nephrol, 22, 232‐A
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Metadata
- Authors
- Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-03-28
- Volume
- 15
- Issue
- 5
- Pages
- 463-473
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2077038286
- Cited by
- 487
- References
- 25
- FWCI
- 57.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.